VARUNContact

Press room.

Source-linked material for accurate coverage.

Biographies, verifiable facts, current roles, reference images and a classified publication record. Earlier publisher bylines are mapped on the evidence-indexed biography.

Prepare a media enquiry Download media facts
Last reviewed 8 September 2026 · Corrections remain visible

Latest publication record · September 2026

Medicines, AI and the work ahead.

Listen, read the original context, then keep the publication boundary visible. None of these records is a partnership, endorsement or product-readiness assessment.

Biographies

Select length

Varun Sharma is the Glasgow-born founder, CEO and CTO of NEUVIOR and product architect of PHARMORIS. A British-Indian entrepreneur, he is building medicines intelligence while developing the VARUNÉ portfolio across biosystems, space systems, AI and robotics. VARUNÉ Labs is a predevelopment programme operated by NEUVIOR.

Read full biography

Quick facts

Public name
Varun Sharma
Current roles
Founder, CEO & CTO, NEUVIOR
Product architect, PHARMORIS
Base
United Kingdom
Focus
Medicines systems, responsible AI and accountable innovation
Innovation-support boundary
NEUVIOR has been selected for non-dilutive support for defined R&D project work. This site links only project-level information already in the public domain. Maximum award value, eligible project cost, company contribution and cash received are different facts; Award ceilings and eligible project costs are not cash received, revenue, customer adoption or outcomes.
Name note
Use Varun Sharma in current coverage, titles and metadata. Earlier publisher bylines are mapped on the evidence-indexed biography.

Complete publication record

Publication record. Exact labels.

Publisher names identify linked records. Access notes, historical-name attributions and derivative relationships appear where they change how a record should be read.

Outlet names identify publishers of the linked records. Their inclusion does not imply endorsement, sponsorship, partnership or approval.

Commentary, letters and appearances

Written by Varun, featuring him, or built around his attributable contribution. These are not presented as independent reporting.

Contributed articleExpress PharmaFrom capacity to capability: Five proofs for India’s pharma futureBy Varun SharmaContributed commentary; the original article is available from Express Pharma.Podcast appearanceAI Ethics Now · University of Warwick IATLAI and Accountability: When Does a Suggestion Become a Decision?Guest: Varun SharmaPodcast participation does not imply University of Warwick endorsement, partnership or product assessment.Contributed views and analysispharmaphorumApproval is not access: Pilots’ real test is implementationBy Varun SharmaContributed analysis, not independent reporting about NEUVIOR or evidence of PHARMORIS adoption.Contributed opinionTechRadar ProFive questions to test whether an AI stack is truly under your controlBy Varun SharmaContributed opinion; publication is not independent validation of NEUVIOR or its systems.Contributed commentaryETPharmaIndia’s pharma quality reset will be won after the inspector leavesBy Varun Sharma · May prompt for sign-inPublished letterFinancial TimesLetter: The real test is whether invention leads to adoptionEarlier publisher byline; identity mapping is documented on the biography page · Subscriber accessExpert commentaryPharmaceutical TechnologyWhy the India-UK trade deal now needs a five-gate implementation ledgerCommentary from Varun Sharma; page byline Ross LawMagazine commentaryPharmaTimesHow we rollEarlier publisher byline; identity mapping is documented on the biography pageContributed commentaryManufacturing ChemistNICE approval is not enough: why the UK’s next medicines challenge is operational deliverySubscriber access beyond the extractContributed commentaryStartups MagazineWhat my dad’s corner shop taught meBy Varun SharmaContributed commentaryBusinessCloudWhy neurodivergent founders can excel at building complex systemsBy Varun Sharma

Reporting and project coverage

Publisher-written reports, news briefs and project-centre coverage. Multiple outlets may cover the same underlying event.

Publisher-written project coverageInsider MediaBusiness secures Innovate UK award for pharmaceutical manufacturing waste projectBy Stephen FarrellPublisher-written news briefDigital HealthDigital Health Coffee Time Briefing ☕Roundup item mentioning NEUVIOR.Publisher-written news briefDaily BusinessStats US growth, Neuvior funds, Balmoral Comtec soldEarlier publisher attribution; identity mapping is documented on the biography pageMulti-story roundup; part of the Scottish Enterprise funding coverage cluster.Publisher-written funding coverageTheBusinessDesk.comGlasgow pharmatech start-up backed by Scottish EnterpriseRegistration-meteredProject coverageBiorenewables Development CentreNEUVIOR advances ZYLON programme following Innovate UK awardProject-centre publication; not presented as independent media reporting.Publisher-written project coverageThe Yorkshire PostNeuvior wins grant to tackle pharmaceutical sector waste with York schemeEarlier publisher attribution; identity mapping is documented on the biography pagePublisher-written project coverageYork PressNEUVIOR Pharmaceuticals new sustainable drug trialsEarlier publisher attribution; identity mapping is documented on the biography page

International follow-on publications

Republication-style or AI-produced derivatives of the five-gate commentary, retained for transparency and not counted as separate original articles.

AI-produced follow-onGeneOnline NewsFive-Gate Framework Proposed for India-UK Pharmaceutical Trade Agreement ImplementationBy GOAI; page states “Powered by GeneOnline AI”Derivative of the Pharmaceutical Technology commentary; not independent reporting.

Publication is evidence of publication. It is not proof of deployment, endorsement, customer adoption or commercial outcome.

Review the wider source-linked record

Media enquiry

Working to a deadline?

Include your outlet, topic and publication date so the request can be prioritised.

Prepare a media enquiry

varun@neuvior.com

Use the same address for fact checks, corrections and image permissions.